Biopharmaceutical Assessment of Active Components of Deadaleopsis confragosa and Ganoderma lucidum


The spread of multidrug-resistant strains of bacteria makes it necessary to discover new classes of antibacterial and compounds that inhibit these resistant mechanisms. Hence, this study investigated the antimicrobial activities of Ganoderma lucidum and Deadaleopsis confragosa extracts against some bacterial isolates of medical importance. Using agar well diffusion assay, aqueous, ethanolic and petroleum ether extracts were obtained from Ganoderma lucidum and Daedaleopsis confragosa and assayed for antimicrobial on five bacterial species, viz: Pseudomonas aeruginosa, Escherichia coli, Staphylococcus aureus, Proteus mirabilis and Klebsiella pneumoniae. In vitro bioassay revealed that the aqueous extract of G. lucidum inhibited P. aeruginosa S. aureus, E. coli and K. Pneumoniae with inhibition zones of 11.0 ± 0.02 mm, 10.0 ± 0.02 mm, 13.0 ± 0.03 mm and 14.0 ± 0.0 mm respectively. The ethanolic extract of G. lucidum also inhibited P. aeruginosa, S. aureus and E. coli with inhibition zones 12.0 ± 0.01 mm, 11.0 ± 0.02 mm and 16.0 ± 0.01 mm. Petroleum ether extract of G. lucidum inhibited P. aeruginosa, S. aureus and E. coli with inhibition zones of 12.0 ± 0.01 mm, 11.0 ± 0.03 mm and 12.0 ± 0.02 mm. For Daedaleopsis confragosa, the aqeous extract inhibited P. aeruginosa and E. coli with inhibition zones of 12.0 ± 0.01 and 12.0 ± 0.02 mm respectively while the petroleum ether extract inhibited S. aureus and E. coli with inhibition zones of 19.0 ± 0.02 mm and 13.0 ± 0.01 mm respectively. All these inhibitions on clinical isolates are therefore attributed to the presence of some bioactive compound as shown by the phytochemical screening of the mushrooms which include tannins, phenolics, flavonoids and saponin.

Share and Cite:

S. Fakoya, K. Adegbehingbe and A. Ogundiimu, "Biopharmaceutical Assessment of Active Components of Deadaleopsis confragosa and Ganoderma lucidum," Open Journal of Medical Microbiology, Vol. 3 No. 2, 2013, pp. 135-138. doi: 10.4236/ojmm.2013.32020.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] R. Griffiths, W. Richards, M. Johnson, U. McCann and R. Jesse, “Mystical-Type Experiences Occasioned by Psilocybin Mediate the Attribution of Personal Meaning and Spiritual Significance 14 Months Later,” Journal of Psychopharmacology, Vol. 22, No. 6, 2008, pp. 621-632. doi:10.1177/0269881108094300
[2] U. Lindequist, T. H. J. Niedermeyer and W. D. Julich, “The Pharmacological Potential of Mushrooms—Review,” Evidence-Based Complementary and Alternative Medicine, Vol. 2, No. 3, 2005, pp. 285-299. doi:10.1093/ecam/neh107
[3] J. W. Bennett and M. Klich, “Mycotoxins,” Clinical Microbiology Reviews, Vol. 16, No. 3, 2003, pp. 497-516. doi:10.1128/CMR.16.3.497-516.2003
[4] C. Hsieh and F. Yang, “Reusing Soy Residue for the Solid-State Fermentation of Ganoderma lucidum,” Bioresource Technology, Vol. 91, No. 1, 2004, pp. 105-109. doi:10.1016/S0960-8524(03)00157-3
[5] J. L. Mau, H. C. Lin and C. C. Chen, “Non-Volatile Components of Several Medicinal Mushrooms,” Food Research International, Vol. 34, No. 6, 2001, pp. 521-526. doi:10.1016/S0963-9969(01)00067-9
[6] Y. Masuda, Y. Murata, M. Hayashi and H. Nanba, “Inhibitory Effect of MD-Fraction on Tumor Metastasis: Involvement of NK Cell Activation and Suppression of Intercellular Adhesion Molecule (ICAM)-1 Expression in Lung Vascular Endothelial Cells,” Biological & Pharmaceutical Bulletin, Vol. 31, No. 6, 2008, pp. 1104-1108. doi:10.1248/bpb.31.1104
[7] A. T. Borchers, A. Krishnamurthy, C. L. Keen, F. J. Meyers and M. E. Gershwin, “The Immunobiology of Mushrooms,” Experimental Biology and Medicine, Vol. 233, No. 3, 2008, pp. 259-276. doi:10.3181/0708-MR-227
[8] T. Pillai, C. Nair and K. Janardhanan, “Polysaccharides Isolated from Ganoderma Lucidum Occurring in Southern Parts of India, Protects Radiation Induced Damages Both in Vitro and in Vivo,” Environmental Toxicology and Pharmacology, Vol. 26, No. 1, 2008, pp. 80-85.
[9] C. N. Harold and D. G. Thomas, “Antimicrobial Chemotherapy,” Medical Microbiology, 4th Edition, University of Texas Medical Branch, Galveston, 1996.
[10] C. Perez, M. Pauli and P. Bazerque, “An Antimicrobial Assay by the Agar Well Diffusion Method,” Acta Biologae et Medicine Experimentalis, Vol. 15, 1990, pp. 113-115.
[11] A. E. Sofowora and A. Odebiyi, “Medicinal Plants and Traditional Medicinal in Africa,” 2nd Edition, Spectrum Books Ltd., Ibadan, 1993, pp. 134-156.
[12] J. H. Zar, “Biostatistical Analysis,” Prentice-Hall, Upper Saddle River, 1984.
[13] B. Boh, M. Berovic, J. Zhang and L. Zhi-Bin, “Ganoderma lucidum and Its Pharmaceutically Active Compounds,” Biotechnology Annual Review, Vol. 13, 2007, pp. 265-301. doi:10.1016/S1387-2656(07)13010-6
[14] B. U. Shamaki, U. K. Sandabe, I. A. Fanna, O. O. Adamu, Y. A. Geidam, I. I. Umar, M. S. Adamu, “Proximate Composition, Phytochemical and Elemental Analysis of Some Organic Solvent Extract of The Wild Mushroom Ganoderma lucidum,” Journal of Natural Sciences Research, Vol. 2, No. 4, 2012.
[15] S. Sekaran, S. Elumalai, B. Ramalingam and K. Devendiran, “Evaluation of Antibacterial and Antifungal Activity of Ganoderma lucidum (curtis) p. Karst Fruit Bodies Extracts,” World Journal of Science and Technology, Vol. 1, No. 6, 2011, pp. 8-11.

Copyright © 2023 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.